{Reference Type}: Journal Article
{Title}: Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.
{Author}: Guerini-Rocco E;Venetis K;Cursano G;Mane E;Frascarelli C;Pepe F;Negrelli M;Olmeda E;Vacirca D;Ranghiero A;Trapani D;Criscitiello C;Curigliano G;Rolfo C;Malapelle U;Fusco N;
{Journal}: Crit Rev Oncol Hematol
{Volume}: 201
{Issue}: 0
{Year}: 2024 Jun 23
{Factor}: 6.625
{DOI}: 10.1016/j.critrevonc.2024.104427
{Abstract}: Mutations in the estrogen receptor alpha gene (ESR1) can lead to resistance to endocrine therapy (ET) in hormone receptor-positive (HR+)/ HER2- metastatic breast cancer (MBC). ESR1 mutations can be detected in up to 40 % of patients pretreated with ET in circulating tumor DNA (ctDNA). Data from prospective randomized trials highlight those patients with HR+/HER2- MBC with detectable ESR1 mutations experience better outcomes when receiving novel selective estrogen receptor degraders (SERDs). There is a high need for optimizing ESR1 testing strategies on liquid biopsy samples in HR+/HER2- MBC, including a hugh quality workflow implementation and molecular pathology reporting standardization. Our manuscript aims to elucidate the clinical and biological rationale for ESR1 testing in MBC, while critically examining the currently available guidelines and recommendations for this specific type of molecular testing on ctDNA. The objective will extend to the critical aspects of harmonization and standardization, specifically focusing on the pathology laboratory workflow. Finally, we propose a clear and comprehensive model for reporting ESR1 testing results on ctDNA in HR+/HER2- MBC.